THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.
Biomarkers
Breast cancer
CRISPR-dCas9
DNA methylation
THOR
hTERT
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
18 12 2022
18 12 2022
Historique:
received:
23
04
2022
accepted:
02
12
2022
entrez:
18
12
2022
pubmed:
19
12
2022
medline:
21
12
2022
Statut:
epublish
Résumé
Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of death among women worldwide. Early BC is potentially curable, but the mortality rates still observed among BC patients demonstrate the urgent need of novel and more effective diagnostic and therapeutic options. Limitless self-renewal is a hallmark of cancer, governed by telomere maintenance. In around 95% of BC cases, this process is achieved by telomerase reactivation through upregulation of the human telomerase reverse transcriptase (hTERT). The hypermethylation of a specific region within the hTERT promoter, termed TERT hypermethylated oncological region (THOR) has been associated with increased hTERT expression in cancer. However, its biological role and clinical potential in BC have never been studied to the best of our knowledge. Therefore, we aimed to investigate the role of THOR as a biomarker and explore the functional impact of THOR methylation status in hTERT upregulation in BC. THOR methylation status in BC was assessed by pyrosequencing on discovery and validation cohorts. We found that THOR is significantly hypermethylated in malignant breast tissue when compared to benign tissue (40.23% vs. 12.81%, P < 0.0001), differentiating malignant tumor from normal tissue from the earliest stage of disease. Using a reporter assay, the addition of unmethylated THOR significantly reduced luciferase activity by an average 1.8-fold when compared to the hTERT core promoter alone (P < 0.01). To further investigate its biological impact on hTERT transcription, targeted THOR demethylation was performed using novel technology based on CRISPR-dCas9 system and significant THOR demethylation was achieved. Cells previously demethylated on THOR region did not develop a histologic cancer phenotype in in vivo assays. Additional studies are required to validate these observations and to unravel the causality between THOR hypermethylation and hTERT upregulation in BC. THOR hypermethylation is an important epigenetic mark in breast tumorigenesis, representing a promising biomarker and therapeutic target in BC. We revealed that THOR acts as a repressive regulatory element of hTERT and that its hypermethylation is a relevant mechanism for hTERT upregulation in BC.
Sections du résumé
BACKGROUND
Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of death among women worldwide. Early BC is potentially curable, but the mortality rates still observed among BC patients demonstrate the urgent need of novel and more effective diagnostic and therapeutic options. Limitless self-renewal is a hallmark of cancer, governed by telomere maintenance. In around 95% of BC cases, this process is achieved by telomerase reactivation through upregulation of the human telomerase reverse transcriptase (hTERT). The hypermethylation of a specific region within the hTERT promoter, termed TERT hypermethylated oncological region (THOR) has been associated with increased hTERT expression in cancer. However, its biological role and clinical potential in BC have never been studied to the best of our knowledge. Therefore, we aimed to investigate the role of THOR as a biomarker and explore the functional impact of THOR methylation status in hTERT upregulation in BC.
RESULTS
THOR methylation status in BC was assessed by pyrosequencing on discovery and validation cohorts. We found that THOR is significantly hypermethylated in malignant breast tissue when compared to benign tissue (40.23% vs. 12.81%, P < 0.0001), differentiating malignant tumor from normal tissue from the earliest stage of disease. Using a reporter assay, the addition of unmethylated THOR significantly reduced luciferase activity by an average 1.8-fold when compared to the hTERT core promoter alone (P < 0.01). To further investigate its biological impact on hTERT transcription, targeted THOR demethylation was performed using novel technology based on CRISPR-dCas9 system and significant THOR demethylation was achieved. Cells previously demethylated on THOR region did not develop a histologic cancer phenotype in in vivo assays. Additional studies are required to validate these observations and to unravel the causality between THOR hypermethylation and hTERT upregulation in BC.
CONCLUSIONS
THOR hypermethylation is an important epigenetic mark in breast tumorigenesis, representing a promising biomarker and therapeutic target in BC. We revealed that THOR acts as a repressive regulatory element of hTERT and that its hypermethylation is a relevant mechanism for hTERT upregulation in BC.
Identifiants
pubmed: 36529814
doi: 10.1186/s13148-022-01396-3
pii: 10.1186/s13148-022-01396-3
pmc: PMC9759897
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Subventions
Organisme : CIHR
ID : MOP-137899
Pays : Canada
Informations de copyright
© 2022. The Author(s).
Références
Science. 2013 Feb 22;339(6122):957-9
pubmed: 23348506
Br J Cancer. 1999 Jul;80(9):1332-41
pubmed: 10424733
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
Int J Cancer. 2002 Oct 1;101(4):335-41
pubmed: 12209957
Pharmacol Ther. 2017 May;173:118-134
pubmed: 28188812
Exp Mol Med. 2015 Jun 05;47:e166
pubmed: 26045254
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet Oncol. 2008 Aug;9(8):730-56
pubmed: 18639491
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Nat Biotechnol. 2015 May;33(5):510-7
pubmed: 25849900
J Natl Cancer Inst. 2018 Jun 1;110(6):560-567
pubmed: 29659933
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Pathology. 2017 Feb;49(2):111-119
pubmed: 28040199
Nat Biotechnol. 2014 Apr;32(4):347-55
pubmed: 24584096
Am J Pathol. 2013 Oct;183(4):1052-1063
pubmed: 23899662
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Cell. 2016 Sep 22;167(1):233-247.e17
pubmed: 27662091
Elife. 2017 May 29;6:
pubmed: 28553926
Cancer Res. 2007 Jan 1;67(1):194-201
pubmed: 17210699
Nucleic Acids Res. 2000 Jul 1;28(13):2557-62
pubmed: 10871406
Nat Biotechnol. 2010 Oct;28(10):1057-68
pubmed: 20944598
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Cancer Res. 2013 Apr 1;73(7):2025-30
pubmed: 23536562
Clin Cancer Res. 2000 Feb;6(2):452-9
pubmed: 10690523
Oncogenesis. 2015 Dec 14;4:e176
pubmed: 26657580
Nat Biotechnol. 2016 Oct;34(10):1060-1065
pubmed: 27571369
Eur J Breast Health. 2017 Oct 01;13(4):162-167
pubmed: 29082372
Anticancer Res. 2004 Sep-Oct;24(5B):3221-4
pubmed: 15510614
Virchows Arch. 2012 Feb;460(2):131-40
pubmed: 22270699
J Clin Invest. 2019 Jan 2;129(1):223-229
pubmed: 30358567
Oncotarget. 2017 Aug 24;8(44):77540-77551
pubmed: 29100407
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Med Oncol. 2016 Mar;33(3):23
pubmed: 26833480
Clin Chem. 1993 Apr;39(4):561-77
pubmed: 8472349
Biochem Biophys Res Commun. 2004 Dec 17;325(3):1037-43
pubmed: 15541393
Methods. 2013 Jan;59(1):S20-3
pubmed: 23036330
Genome Biol. 2015 May 22;16:107
pubmed: 25994018
Cancer Sci. 2008 Aug;99(8):1528-38
pubmed: 18754863
Cell. 2014 Oct 23;159(3):635-46
pubmed: 25307933
Breast Cancer. 2018 May;25(3):292-296
pubmed: 29222734
Oncotarget. 2016 Sep 6;7(36):57726-57736
pubmed: 27437772
Genes (Basel). 2018 May 03;9(5):
pubmed: 29751586
Am J Clin Oncol. 2000 Aug;23(4):386-92
pubmed: 10955870
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
PLoS One. 2014 Feb 14;9(2):e86990
pubmed: 24551047
Nat Rev Genet. 2016 Sep 15;17(10):630-41
pubmed: 27629931
J Pathol. 2002 Oct;198(2):181-9
pubmed: 12237877
Exp Mol Pathol. 2016 Apr;100(2):287-93
pubmed: 26626802
Sci Rep. 2017 May 25;7(1):2409
pubmed: 28546538
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
J Clin Oncol. 2013 Mar 1;31(7):961-5
pubmed: 23129741
Eur J Cancer. 2017 Apr;75:284-298
pubmed: 28259011
Cell Discov. 2016 May 03;2:16009
pubmed: 27462456
Int J Oncol. 1998 Mar;12(3):641-8
pubmed: 9472105
Future Oncol. 2017 Oct;13(23):2045-2051
pubmed: 29019414
Int J Cancer. 2019 Apr 1;144(7):1676-1684
pubmed: 30350309
Cell. 2014 Jun 5;157(6):1262-1278
pubmed: 24906146
Front Med (Lausanne). 2017 Dec 08;4:227
pubmed: 29276709
Lancet Oncol. 2013 May;14(6):534-42
pubmed: 23598174
Nat Commun. 2013;4:2185
pubmed: 23887589
Tumour Biol. 2014 May;35(5):4087-93
pubmed: 24375252
Mod Pathol. 2009 Nov;22(11):1423-31
pubmed: 19734843
Breast Cancer Res. 2009;11(6):R88
pubmed: 20003265
Int J Oncol. 2016 Dec;49(6):2199-2205
pubmed: 27779655
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Cancer. 2005 Nov;5(11):845-56
pubmed: 16239904
Oncotarget. 2016 Jul 19;7(29):46545-46556
pubmed: 27356740
Cancer Res. 2014 Apr 15;74(8):2160-70
pubmed: 24737128
Nucleic Acids Res. 2016 Jul 8;44(12):5615-28
pubmed: 26969735
Am J Pathol. 2013 Oct;183(4):1113-1124
pubmed: 23993780
Nat Rev Clin Oncol. 2015 Jul;12(7):381-94
pubmed: 25895611
J Biomed Sci. 2018 Mar 12;25(1):22
pubmed: 29526163
Oncogene. 2002 Jan 21;21(4):688-97
pubmed: 11850797
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Cancer Cell. 2013 Jan 14;23(1):9-22
pubmed: 23245995
Nat Med. 2017 Aug;23(8):984-989
pubmed: 28714989